pre-IPO PHARMA

COMPANY OVERVIEW

Nkarta Therapeutics was founded on the proprietary, robust and well characterized Natural Killer (NK) cell expansion technology pioneered by Dario Campana. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to build differentiated allogeneic cell therapy candidates for the treatment of cancer. Founded in 2015, the company’s investors include SR One, NEA and Novo Ventures.


LOCATION

  • South San Francisco, MA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.nkartatx.com


    CAREER WEBSITE

    https://www.nkartatx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    nea novo-holdings sr-one


    PRESS RELEASES


    Jun 14, 2021

    Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term


    Jun 22, 2020

    Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II


    Apr 27, 2020

    Nkarta Therapeutics Appoints Two New Independent Directors


    Jan 9, 2020

    Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference


    Dec 9, 2019

    Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development


    For More Press Releases


    Google Analytics Alternative